Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05963191

CAD-EYE System for the Detection of Neoplastic Lesions in Patients With Lynch Syndrome

Lynch syndrome (LS) is the most common genetic predisposition syndrome for colorectal cancer (CRC), responsible for around 2-4% of cancers. It is characterized by a pathogenic germline mutation in one of the DNA mismatch repair genes (path_MMR) MLH1, MSH2, MSH6, PMS2 or a deletion in the 3' region of the Epcam gene. Patients followed up for LS are at high risk of developing CRC at an early age, and have a high cumulative CRC risk. In this context, CRC screening by colonoscopy is of major importance, as it is associated with a reduction in both CRC incidence and mortality.

In France, the Institut National du Cancer (INCa) recommends colonoscopy with indigo carmine chromoendoscopy (CE), as it is associated with a significant increase in the adenoma detection rate (ADR) compared with white light. However, EC is not routinely performed in clinical practice, as it is a time-consuming technique requiring a dedicated slot with a trained operator.

Recent years have seen the emergence of artificial intelligence techniques for real-time polyp detection aids or CADe devices. These easy-to-use systems have shown very promising results compared with high-definition (HD) white light. Indeed, data from the first meta-analysis of 5 randomized controlled trials (4354 patients) confirmed a significantly higher ADD in the CADe group than in the HD group (36.6% vs. 25.2%; 95% CI], 1.27-1.62; P < 0.01; I2 Z 42%) 10. The CAD EYE system (Fujifilm) is a CADe device supporting both detection (sensitivity > 95%) and characterization of colonic polyps in real time.

To date, artificial intelligence has never been evaluated for CRC screening in patients followed up for LS. The aim of this work is to evaluate the effectiveness of the CAD EYE system in this specific population. To this end, we intend to conduct a randomized, controlled, non-inferiority trial comparing CAD EYE with CE in patients with LS.

Recruiting

Interested in participating?

Request Info

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Confirmed pathogenic mutation (path_MLH1, path_MSH2, path_MSH6, path_PMS2, path_EpCAM)
  • Male or female of legal age at time of colonoscopy prescription.
  • Patient agreeing to participate in the study
  • Person affiliated with or benefiting from a social security scheme
  • Free, informed and express consent

Exclusion criteria

  • Patient undergoing total colectomy with ileoanal or ileosigmoid anastomosis
  • Patient with a history of Crohn's disease or ulcerative colitis
  • Patients with a known allergy or intolerance to polyethylene glycol and ascorbic acid.
  • Patients unable to undergo fractionated colonic preparation
  • Inadequate colonic preparation: Boston sub-score <2 per segment
  • Patient under guardianship or protected person
  • Patient who does not understand French or cannot read
  • Person not affiliated to a Social Security system.
  • Pregnant women

Treatment and study plan

Colorectal cancer screening with CAD EYE colonoscopy

Device

The colonoscopy procedure for each patient will be no different from a conventional colonoscopy examination. A colonoscopy is considered complete if the endoscope reaches the appendicular orifice or the terminal ileum. In line with recommendations, water lavage (using a lavage pump) and aspiration of food residues will be performed on ascent and/or descent to visualize the entire colonic mucosa.

In the CAD EYE group, descent is performed under white light, with the CAD EYE system switched on. When polyps are detected, they are rigorously described and histological predictions of endoscopist and CAD EYE will be reported separately. Then polyps will be removed by polypectomy or mucosectomy. Removed polyps are then sent for anatomopathological analysis.

Primary outcomes

  1. to evaluate the effectiveness of the CAD EYE system in screening for neoplastic lesions in Lynch syndrome.

    Time frame: Through study completion, an average of 2 years

    Comparison of the adenoma detection rate (ADR) between the CAD-EYE group and the indigo carmin chromoendoscopy (CE) group (reference technique).

Secondary outcomes

  1. Detection rates of specific lesions

    Time frame: Through study completion, an average of 2 years

    Mean number of adenomas and serrated lesions per patient

  2. Diagnostic performance of CAD EYE

    Time frame: Through study completion, an average of 2 years

    Comparison of the diagnostic performance of CAD EYE assessed by specificity, negative predictive value and positive predictive value for the characterization (adenoma/hyperplastic) of colonic polyps with the CAD EYE automated detection system. The anatomopathology of polyps was taken as the diagnostic reference.

  3. Rate of resect and discard strategy

    Time frame: Through study completion, an average of 2 years

    Evaluation of the feasibility of a "resect and discard" strategy in Lynch Syndrome. Retrospective analysis comparing CAD-EYE histological prediction vs. endoscopist prediction, using histological report as reference examination (Sensitivity and negative predictive value).

  4. Time of Colonoscopies

    Time frame: Through study completion, an average of 2 years

    Comparison of different procedure times between the 2 groups. Total procedure time will be defined as the time from endoscope insertion to extraction through the anus. Withdrawal time will be defined as the time spent on inspection, from the cecum to extraction of the endoscope through the anus, excluding the time required for polypectomy.

Study contacts

Contact information is provided by the study sponsor or research team.

Guillaume Perrod, MD

CONTACT

[email protected]

+33 1 56 09 34 17

Sponsors and collaborators

Lead sponsor

PERROD Guillaume

Other

Registry information

Official study title

Evaluation of the CAD-EYE System for the Detection of Colorectal Neoplastic Lesions in Patients With Lynch Syndrome

Acronym: CADLYNCH

Important dates

Study start
2024
Primary completion
2025
Study completion
2026
First posted
Jul 27, 2023
Registry last updated
Sep 3, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.